"The most profitable route would be to invest into the development of new molecules, but we are not there yet. Given these circumstances, we need to focus our innovation efforts within the existing molecules. The vision of our industry should not be limited to sub-contracted production."

Hasan Ulusoy

CHAIRMAN, NOBEL İLAÇ

May 14, 2020

Nobel distinguishes itself not only as one of the largest indigenous pharma companies, but also the only one which doesn’t run a trade deficit. What has secured Nobel’s success in export markets?

Nobel’s presence in foreign markets dates back to the 1990s and, in the past decade, we have been exporting more than importing, at a time when the Turkish pharma industry incurs an annual current deficit of around US$4 billion. Nobel relies on a team of 1,500 employees in 20 countries other than Turkey, with production in two of these countries. But it hasn’t always been plain sailing. We experienced major challenges in every place we started our operations, yet we were perseverant and maintained our commitment. This year, we are the national leaders in drug exports.

How do you believe Turkey could increase its exports and compete in the global market? Are current initiatives in the right direction?

The most profitable route would be to invest into the development of new molecules, but we are not there yet. Given these circumstances, we need to focus our innovation efforts within the existing molecules. The vision of our industry should not be limited to sub-contracted production.

Reflecting on Nobel’s evolution since its foundation in 1964, what do you identify as some of the most significant crossroads in its growth?

Nobel’s activities started in 1964, and the company was integrated under Ulkar Holding in 1979. At the turn of the millennium, Nobel moved production to Düzce and opened the first office abroad, in Uzbekistan, which was to become the first GMP certified production site in that country. Since our facilities obtained the EU GMP certificate, we went on a growth ramp, with one of our products, Etol, becoming Turkey’s highest turnover pharmaceutical. The latest focus at Nobel is our investment in biotechnological and high utility products. In this sense, Nobel joined the Turquality programme in 2014, before starting orphan drugs which were previously dependent on imports in Turkey.  

Nobel is the first company supported by the government in the development of biosimilars in line with the 2023 vision. What is the progress made by the company in this sense?

Nobel was the only file selected out of the 28 applications of 23 pharma companies submitted to the bid for “development and production of biosimilars” led by TÜBITAK (The Scientific and Technological Research Council of Turkey). To me, the sine qua non requirement to exist in the future is to be present in the biotechnology market. Market share of biotechnological products has already reached 20% in our country and I have no doubts it will account for 50% very soon. We are determined to be an important player in this segment.

What significance does the Turquality program have for its members?

The Turquality program was designed with a view to create Turkish brands in the global market. It is a project devised to find a solution to the chronic current account deficit problem of our country, and so far it has been an encouraging initiative for the industry.

Investing 5% of its revenues in R&D, and having started the knowledge sharing platform Nobel Medicus, Nobel has played an important role in driving innovation in Turkey. How do you consider Turkey could increase its innovation agenda?

Nobel indeed spares around 5% of turnover every year for R&D activities, but we would like to allocate more, should the conditions permit- that is, if we were not squeezed under price pressures. Nobel Medicus is a unique, peer-reviewed, impartial and free-of-charge journal in our industry. Alike Medicus, I can come up with numerous suggestions for our country’s innovation journey, but they all boil down to the same starting point: creating an innovation climate in which every corner of our country as well as the brains of every person operating in the field could act to create an incubation centre. This should be a priority for our country.

What is the vision for Nobel in the coming years and do you have a final message for our audience?

Our vision is “to provide reliable and accessible products for human health at every corner of the world”. We have strived for more than half a century for this goal, and we hope to continue in the same line for yet another 50 years and beyond.

INTERVIEWS MORE INTERVIEWS

"There is a consensus that large new deposits like Escondida are rare, but the development of multiple medium-sized mines, possibly centralized around shared infrastructure, offers a significant opportunity."
"Our jurisdictional diversification is certainly a defining characteristic of Thor, but so is the fact that our projects are also diversified by stage of development."
"Port Houston’s strategic location and extensive services make it the leading gateway for waterborne trade between Latin America and the US."
"Paradigm lets us run the entire blast digitally before we even drill or lay out the shot. We can simulate a model for fly rock risk, predict ground vibrations, and evaluate how blasting might impact neighbors or nearby infrastructure."

RECENT PUBLICATIONS

Québec and Atlantic Canada Mining 2025

Québec and Atlantic Canada have traversed 2025 in an enviable position. Strong gold prices have buoyed balance sheets and investor sentiment, while global demand for critical minerals keeps the region firmly on the radar of international markets. At the same time, the provinces’ depth of mining expertise – from AI-driven exploration to advanced drilling, blasting, and geophysics – ensures that technological advantage is firmly on their side.

MORE PREVIOUSLY PUBLISHED

MACIG

"Our jurisdictional diversification is certainly a defining characteristic of Thor, but so is the fact that our projects are also diversified by stage of development."

SUBSCRIBE TO OUR NEWSLETTER